ADIPOQ and Insulin resistance: Thiazolidinediones (TZDs) decrease insulin resistance directly through activation of PPARγ receptors which facilitate differentiation of mesenchymal stem cells into adipocytes, promote lipogenesis in peripheral adipocytes, decrease hepatic and peripheral triglycerides, decrease activity of visceral adipocytes, and increase adiponectin [18••, 19, 20].